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ABSTRACT
Objective: The aim of this study was to evaluate the
feasibility of laparoscopy in the management of early
stage endometrial cancer.
Methods: Fifty-two patients with endometrial cancer who
underwent surgical staging consisting of total hysterec-
tomy, bilateral salpingo-oophorectomy with pelvic lymph
node dissection, and cytology between 1998 to 2002 were
included in the study. Laparotomy and laparoscopy were
randomly offered to patients upon admittance.
Results: Of 52 patients, 26 underwent laparotomy and the
remaining 26 underwent laparoscopic staging surgery. No
significant difference existed between the demographic
characteristics of the 2 groups. The mean number of
harvested lymph nodes was 18.2 in the laparoscopic
group and 21.1 in the laparotomic group (P0.05). Pelvic
lymph node metastases were detected in 7.7% of the
patients in the laparoscopy group and 15.4% in the lapa-
rotomy group, and the difference was not significant.
Adjuvant radiotherapy was applied later to 42.3% of the
laparoscopy group and 38.5% of the laparotomy group.
Operative morbidity was higher in the laparotomy group
mainly because of postoperative wound infection, and the
patients in the laparotomy group had a longer hospital
stay.
Conclusion: Laparoscopic surgery is a method that can
be applied as well as laparotomy in the management of
endometrial cancer. Lymph node number and detection of
lymph node metastasis did not differ significantly in lapa-
rotomic and laparoscopic approaches. Wound infections
were more frequent in laparotomies.
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INTRODUCTION
The incidence of endometrial cancer has remained stable,
but the number of deaths annually from this disease has
doubled since 1987.1 Despite the fact that many gynecol-
ogists believe endometrial cancer is harmless, when com-
pared stage by stage, 5-year survival is identical to that of
cervical cancer, which is considered virulent. Thus, we are
obligated to reassess the screening, diagnostic, staging,
and therapeutic aspects and most importantly the debate
on lymphadenectomy during hysterectomy. Currently, an
extremely low prevalence is inferred for lymph node in-
volvement in stages Ia, Ib, and grade 1 neoplasm, which
comprises 40% to 60% of newly diagnosed patients.
Therefore, the removal of regional reactive lymph nodes
in this setting seems inappropriate. Furthermore, it is pos-
tulated that in early disease stages and when regional
nodes are clinically unaffected, nodes should only be
sampled for prognostic significance and not removed rad-
ically in the vain hope of curing the patient. Indeed,
evidence from laboratory studies has shown that many
lymphatic and lymphatico-venous shunts that bypass re-
gional lymph nodes exist and allow an early stage lym-
phatic and hematogenous dissemination of malignant
cells.2–6 On the other hand, removal of lymph nodes if
they are grossly positive, lessening the tumor burden,
should decrease the amount of suppressive tumor anti-
gens present in the host and reduce the amount of ad-
junctive therapy required to treat residual disease. Indeed,
ineffective nodes are no longer useful to the host but now
contribute to increased tumor-induced immunologic sup-
pression.7
For tumors infiltrating the inner third of the myometrium,
the actual risk of node metastases is substantial for grade
3 histologic type tumors, and for the middle third inva-
sion, the risk of node metastases is substantial for grade 2
and 3 lesions. For tumors infiltrating the outer third, the
risk is substantial for all. Thus, the risk is ignorable for
superficial invasion and substantial for deep myometrial
invasion for all grades (20% to 45%). The negligible risk of
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SCIENTIFIC PAPERnode metastases (0% to 4%) is also valid for inner one-
third myometrial involvement for grades 1 and 2, for
middle one-third involvement with grade 1 tumors, and
for all aforementioned conditions with no vascular space
involvement and no spread to the cervix or adnexa, or
both, with histologic type adenocarcinoma and adenoac-
anthoma. This group comprises 75% of patients. Never-
theless, the common belief among gynecologists of “just
to take out the uterus as it is small and well differentiated”
is not valid as 10% to 15% of the grade 1 lesions have
substantial myometrial invasion exposing the patient to
substantial risk for node metastases and thereby necessi-
tating intraoperative assessment of myometrial invasion in
those instances as well.
Thus, the need for lymph node assessment during surgery
is the most challenging issue among gynecologists. Sec-
ondly, what is the best way to assess lymph nodes is
another debate. Several methods of lymph node dissec-
tion have been proposed for different situations although
these differ from one surgeon to the next. The adequacy
of clinical assessment of lymph nodes and sampling
lymphadenectomy has been a subject of controversy for
years. Meticulous inspection and palpation bidigitally are
refined exercises for the gynecologic oncologist, but
slightly more than one half of the suspicious pelvic and
paraaortic nodes reveal metastases while only 5% of the
unsuspicious nodes bear malignant cells.8 Thus, one
should bear in mind the possibility of undetected metas-
tases of regional nodes by traditional methods during
surgery. In addition, some tumor cells can only be de-
tected by immuno-histochemical analysis and thereby
pass unrecorded. Thus, the real incidence of tumor in-
volvement might have been underestimated due to the
technique used for pathologic assessment and limited
node dissection. “Do we need to do complete dissection
for positive detection, because negative staging does not
necessarily identify a subset that does not need further
therapy” is another debate. On the other hand, the con-
cern about “what would be the false negativity rate to be
accepted by the surgeon and the patient?” is another
important issue. The question arises of morbidity assess-
ment after lymph node evaluation for that individual.
These issues must be discussed with the patient in detail
before surgery.
Hence, being the most prevalent gynecological cancer,
endometrial cancer does not require a radical hysterec-
tomy but lymph node evaluation in its early stage. As
gynecologic oncology surgeons have gained more expe-
rience and skill in different techniques and procedures,
and more interest in minimally invasive surgery, the lapa-
roscopic approach has found applications in the treatment
of endometrial cancer. With the application of video and
improvement in the armamentarium of video, laparo-
scopic surgery changed from being performed in an op-
erating room by one man frustrated because of the lack of
the ability of other operating room staff to follow and
participate in this surgical procedure, to being performed
in an amphitheater, allowing not only the assistant and
other operating room staff to see the actual procedure and
follow the sequences but also assist the surgeon better.
These advances resulted in accelerated improvement in
operative laparoscopy and proved to be an important aid
to education because of the advantage of using monitors
during the operation and taping the surgery for repetitive
education.
Laparoscopic-assisted surgical staging (LASS) of early
stage endometrial cancer, although remaining a contro-
versial subject, is an attractive alternative to the traditional
laparotomic approach. Nevertheless, one should bear in
mind that the first purpose of the staging is to provide a
common language and uniformity for comparison instead
of aiding therapy and management issues. Thus, standard-
izing “the needed and not needed” for staging must be the
first aim despite there still existing some conflicting ideas
regarding the system of staging.
Laparoscopy has a similar success rate when compared
with laparotomic staging, and it can be accepted as less
invasive. Studies have shown that the lymph node yield
from laparoscopy is equivalent to that of laparotomy.
Feasibility of laparoscopic staging in incompletely staged
endometrial cancer patients is another subject of interest.
Although laparoscopic pelvic and paraaortic lymphade-
nectomy is accepted as feasible, randomized studies are
still awaited to standardize its indications and applica-
tions.
METHODS
The patient population consisted of 52 early stage endo-
metrial cancer patients who presented to Akdeniz Univer-
sity Obstetrics and Gynecology Department between 1998
and 2002. All underwent staging surgery comprising total
hysterectomy, bilateral salpingo-oophorectomy, and pel-
vic lymph node sampling by the same 2 surgeons (CGZ,
TS), using the same technique and instruments. The pa-
tients were randomly assigned to the surgical approach
and informed before surgery about the type of surgery
they were to undergo. One group comprised 26 patients
managed by traditional laparotomic surgery, while the
other comprised 26 patients who underwent laparoscopic
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advanced disease were not included in the study. The
main outcomes studied were operative time, blood trans-
fusion, intraoperative and postoperative complications,
duration of hospital stay, number of lymph nodes ob-
tained and lymph node positivity. Statistical analysis was
performed by the Mann Whitney U Test, and P values
0.05 were considered statistically significant.
RESULTS
The demographic characteristics were not statistically sig-
nificant between the 2 groups. The laparotomy group had
an average age of 54.9 (range, 36 to77) and an average
gravidity of 3.8 (range, 0 to 9). The laparoscopy group had
an average age of 56.6 (range, 40 to 72) and an average
gravidity of 3.6 (range, 0 to 8). Body mass indexes were
not significantly different between laparotomy and lapa-
roscopy groups, being 26.2 vs 24.4 respectively.
The majority of the patients had stage I disease (67.3%),
and endometrioid type of endometrial cancer was more
common (Tables 1, 2, and 3). The average number of
harvested lymph nodes in each patient was also com-
pared. The number of lymph nodes was not significantly
different between the groups (P0.05). The laparoscopic
group had an average number of 18.2 (range, 9 to 31), and
the laparotomic group 21.1 (range, 9 to 38). Two (7.7%)
patients in the laparoscopy group and 4 (15.4%) in the
laparotomy group had pelvic lymph node metastasis.
Eleven patients (42.3%) in the laparoscopy group and 10
(38.5%) in the laparotomy group were later scheduled for
adjuvant radiation therapy.
The laparoscopic group had significantly shorter hospital-
ization than did the laparotomy group (4.1 vs 8.2 days, z
1.96, P0.05). Operative time of laparoscopy being
close to that of laparotomy was encouraging (155 vs 144
minutes, P0.05).
In terms of postoperative and intraoperative complica-
tions, the laparoscopic approach had none, while wound
complications occurred in 5 patients in the laparotomy
group, of which one was evisceration and needed reop-
eration for closure. Eight units of red blood cell suspen-
sion were transfused to the laparotomy group patients and
6 units to the laparoscopy group patients.
DISCUSSION
Nowadays, the laparoscope allows us to carry out almost
any procedure that can be done by laparotomy in gyne-
cologic practice. Laparoscopically assisted vaginal hyster-
ectomies and laparoscopic total hysterectomies for benign
conditions are being applied widely even in patients with
large uteri. However, in the management of gynecologic
cancers, the laparoscope had a lesser role, until pelvic and
paraaortic lymph node dissections became feasible in the
1990s. Following this achievement, the laparoscope has
gained importance among gynecologic oncologists espe-
cially in patients with early endometrial and cervical can-
cers. Nevertheless, the laparoscopic technique was not
well defined or standardized. Every surgeon was doubtful
about the outcome of this type of surgery. Because of such
doubt, many institutions established pilot studies and
some prospective small-scale trials. At any rate, some
were successful with speeded up publication encouraging
Table 1.
Study Groups Compared According to Stage
Stage Laparotomy Group
(n  26)
Laparoscopy Group
(n  26)
I 14 (54%) 21 (80.8%)
II 4 (15%) 2 (7.7%)
III 8 (31%) 3 (11.5%)
Table 2.
Histologic Grades of the Study Groups
Grade Laparotomy Group
(n  26)
Laparoscopy Group
(n  26)
1 14 (54%) 15 (58%)
2 6 (23%) 5 (19%)
3 6 (23%) 6 (23%)
Table 3.
Histologic Types of Endometrial Cancer in the Study Groups
Histologic Type Laparotomy Group
(n  26)
Laparoscopy Group
(n  26)
Endometrioid 20 (77%) 19 (73.1%)
Clear cell 2 (7.7%) 2 (7.7%)
Adenosquamous — 1 (3.8%)
Serous 1 (3.8%) 3 (11.5%)
Mucinous — 1 (3.8%)
Undifferentiated 1 (3.8%) —
Mixed 2 (7.7%) —
Total 26 26
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cally assisted vaginal hysterectomy with lymph node eval-
uation is now an alternative treatment for endometrial
cancer in properly selected patients. The goal is to mini-
mize the morbidity of treatment instead of satisfying sur-
geons’ new enthusiasm to use the technique.
Laparoscopically assisted surgical staging for endometrial
cancer in experienced hands can be performed with equal
success and safety with minimal morbidity. It has the
advantages of less pain, early resumption of normal activ-
ities, and overall improved quality of life. Many authors
are in agreement that it results in significantly less blood
loss and shorter hospitalization. The only drawback seems
to be the longer operating time reported in most stud-
ies.9–11
Scribner et al10 compared laparoscopy and laparotomy in
a similar number of patients as in our study. They con-
cluded that although the early hospital discharge is an
advantage, longer surgical time and higher anesthetic
costs of the laparoscopic approach offset this gain, and
total costs appear not to differ statistically. In contrast to
Scribner’s study, Gemignani et al,11 found the overall
charges in the laparoscopy group significantly lower than
that of laparotomy group, considering fewer postopera-
tive complications seen with the laparoscopic approach, a
factor that lowers overall hospital charges. In these 2
studies, the laparoscopy group had a significantly longer
operating room time (237 vs 157 minutes in Scribner’s
study and 214 vs 144 minutes in Gemignani’s study);
however, in our study, the duration of the operation for
the 2 groups was similar (155 vs 144 minutes).
Another randomized study12 comparing the laparoscopic-
vaginal approach with the conventional abdominal ap-
proach for treatment of patients with endometrial cancer
was performed including 70 patients with endometrial
cancer FIGO stage I-III. Thirty-seven patients were treated
in the laparoscopic group versus 33 patients in the lapa-
rotomy group. Lymph node dissection was performed in
25 patients by laparoscopy and in 24 patients by laparot-
omy. Blood loss and transfusion rates were significantly
lower in the laparoscopic group. Yield of pelvic and
paraaortic lymph nodes, duration of surgery, and inci-
dence of postoperative complications were similar for
both groups. Overall and recurrence-free survival did not
differ significantly for both groups.12
While comparing laparotomy and laparoscopy, the num-
ber of residual nodes following lymphadenectomy has
also been studied because lymph nodes left in situ might
have had microscopic metastases. In a review by Lecuru
and Taurelle,13 laparoscopic pelvic lymphadenectomy
was declared able to retrieve 90% to 95% of the nodes,
which was similar to that of laparotomy. Laparoscopy has
been proven to be adequate and efficient in pelvic lymph-
adenectomy. Laparoscopic paraaortic lymphadenectomy
can be substituted for its open counterpart regarding
lymph node yield and accuracy in recovery of positive
nodes as well.14
Port-site metastases are one of the most often addressed
issues in patients undergoing a laparoscopic procedure
for any kind of gynecologic cancer. Dragging cancerous
tissue through a small incision and exfoliation from the
surface and implantation into the healing wounds are the
main reasons for an increased likelihood of metastases or
recurrences at that sites. However, in gynecologic cancers
port-site recurrences are always associated with either
disseminated intraperitoneal disease or cyst rupture. The
question of contamination and increasing tumor growth
because of CO2 laparoscopy and the effect of pneumo-
peritoneum on survival remains obscure. However, sur-
geons should take some preventive measures, such as
avoiding cyst rupture, gentle handling of the cancerous
tissue, avoiding the rupture of the lymph node capsule,
and including the port sites in the radiation field in pa-
tients undergoing postoperative irradiation. In this study,
no port-site metastases occurred.
Morbidities related only to laparoscopic surgery are of
some concern, and injuries are generally related to trocar
installation. These morbidities are mostly bowel, vascular,
and bladder injuries. Increasing numbers of advanced
laparoscopic applications like expanded lymph node dis-
sections and more radicalness in treating gynecologic can-
cers have caused surgeons to face other complications as
well. Injury to vein tributaries during laparoscopic lymph-
adenectomy may cause major hemorrhage from the adja-
cent veins.15 Pelvic plexus bleeding may also occur be-
cause of inappropriate dissection.16 It might not be easy
sometimes to overcome such bleeding even during lapa-
rotomy because of the depth of the location of bleeding,
preventing easy access to the area. A laparoscope with 5-
to 7-fold magnification could sometimes be superior in
identifying such deep bleeding locations; however, diffi-
culty in suturing or unavailability of vascular clamps may
prevent the appropriate approach. In our study group, no
such complication requiring laparotomy occurred in the
laparoscopically managed patients.
Almost 90% of the patients in the laparoscopy group had
stage I or II disease following surgical staging, whereas
only 70% of the patients in the laparotomy group had
JSLS (2005)9:442–446 445early stage disease. However, the breakout of stage III
subsets showed us that such patients are not identifiable
before surgery, and therefore this could be incidental
because we never felt that “we’re glad that we opened this
patient; it would be dreadful if we put the scope for the
first time during surgery.” We conclude that the laparo-
scope seems to be very useful in a select group as it
reduces postoperative morbidity offering quick recovery
with the same success and efficacy. However, experience
is of the utmost importance, and there is no way to start
scoping without proper training. Feeling ready does not
mean that one will be good in the operating room, and
thus being supervised should not be overlooked before
integrating such a procedure into clinical practice.
CONCLUSION
Laparoscopy is as good as laparotomy in the management
of endometrial cancer. Shorter hospital stay and less post-
operative morbidity are advantages of laparoscopic sur-
gery. Duration of laparoscopic surgery does not seem to
be different from that of laparotomy.
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